Lycurim (R-74) in the therapy of chronic lymphocytic leukaemia.
Lycurim was used in the therapy of 41 CLL patients, in 34 a positive clinical effect was found. The effect was marked in cases of CLL associated with autoimmune haemolytic anaemia. The immunodepressive property of Lycurim was confirmed by immunological investigation. It has been shown that the levels of IgG, IgA and IgM fall after Lycurim treatment of CLL patients. At the same time the T-lymphocyte count decreases and a tendency for EAC rosette-forming B-lymphocyte decrease is marked.
D000328:Adult; D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications / Q000188:drug therapy; D001402:B-Lymphocytes; D001609:Beta-Globulins / Q000096:biosynthesis; D004896:Erythritol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012397:Rosette Formation; D013601:T-Lymphocytes; D005719:gamma-Globulins / Q000096:biosynthesis
D001609:Beta-Globulins; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D005719:gamma-Globulins; D004896:Erythritol; C000288:ritrosulfan